DE60002714D1 - Substituierte azaoxindolederivate - Google Patents
Substituierte azaoxindolederivateInfo
- Publication number
- DE60002714D1 DE60002714D1 DE60002714T DE60002714T DE60002714D1 DE 60002714 D1 DE60002714 D1 DE 60002714D1 DE 60002714 T DE60002714 T DE 60002714T DE 60002714 T DE60002714 T DE 60002714T DE 60002714 D1 DE60002714 D1 DE 60002714D1
- Authority
- DE
- Germany
- Prior art keywords
- compounds
- disease states
- inhibition
- protein
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000005764 inhibitory process Effects 0.000 abstract 2
- SILNNFMWIMZVEQ-UHFFFAOYSA-N 1,3-dihydrobenzimidazol-2-one Chemical class C1=CC=C2NC(O)=NC2=C1 SILNNFMWIMZVEQ-UHFFFAOYSA-N 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 abstract 1
- 208000037273 Pathologic Processes Diseases 0.000 abstract 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 230000001594 aberrant effect Effects 0.000 abstract 1
- 230000008485 antagonism Effects 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 208000022605 chemotherapy-induced alopecia Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000009054 pathological process Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9904995 | 1999-03-04 | ||
| GBGB9904995.9A GB9904995D0 (en) | 1999-03-04 | 1999-03-04 | Substituted aza-oxindole derivatives |
| PCT/US2000/005583 WO2000055159A2 (en) | 1999-03-04 | 2000-03-03 | Substituted aza-oxindole derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60002714D1 true DE60002714D1 (de) | 2003-06-18 |
| DE60002714T2 DE60002714T2 (de) | 2004-03-18 |
Family
ID=10848965
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60002714T Expired - Fee Related DE60002714T2 (de) | 1999-03-04 | 2000-03-03 | Substituierte azaoxindolederivate |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1180105B1 (de) |
| JP (1) | JP2003502280A (de) |
| AT (1) | ATE240328T1 (de) |
| AU (1) | AU3864500A (de) |
| DE (1) | DE60002714T2 (de) |
| ES (1) | ES2199156T3 (de) |
| GB (1) | GB9904995D0 (de) |
| WO (1) | WO2000055159A2 (de) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6624171B1 (en) * | 1999-03-04 | 2003-09-23 | Smithkline Beecham Corporation | Substituted aza-oxindole derivatives |
| US6638965B2 (en) | 2000-11-01 | 2003-10-28 | Boehringer Ingelheim Pharma Kg | Substituted indolinones, preparation thereof and their use as pharmaceutical compositions |
| IL158590A0 (en) | 2001-06-11 | 2004-05-12 | Biovitrum Ab | Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| RS111204A (sr) * | 2002-06-20 | 2006-12-15 | Biovitrum Ab. | Nova jedinjenja korisna za lečenje gojaznosti, šećerne bolesti tipa ii i poremećaja cns |
| US7943639B2 (en) | 2002-06-20 | 2011-05-17 | Proximagen Limited | Compounds |
| RS53109B (sr) | 2003-07-30 | 2014-06-30 | Rigel Pharmaceuticals Inc. | Jedinjenja 2,4 pirimidindiamina za upotrebu u tretmanu ili prevenciji autoimunih bolesti |
| JP4936897B2 (ja) | 2003-12-18 | 2012-05-23 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 抗増殖剤としてのピリド−およびピリミドピリミジン誘導体 |
| SI1753764T1 (sl) | 2004-06-09 | 2009-02-28 | Glaxo Group Ltd | Derivati pirolopiridina |
| AU2005302707A1 (en) * | 2004-10-27 | 2006-05-11 | Janssen Pharmaceutica N.V. | Pyridine imidazoles and aza-indoles as progesterone receptor modulators |
| NI200700147A (es) | 2004-12-08 | 2019-05-10 | Janssen Pharmaceutica Nv | Derivados de quinazolina inhibidores de cinasas dirigidos a multip |
| US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| CN105348203B (zh) | 2005-06-08 | 2018-09-18 | 里格尔药品股份有限公司 | 抑制jak途径的组合物和方法 |
| US8962643B2 (en) | 2006-02-24 | 2015-02-24 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
| MX2009000456A (es) | 2006-07-13 | 2009-01-27 | Janssen Pharmaceutica Nv | Derivados de quinazolina mtki. |
| EP2170827B1 (de) * | 2007-06-21 | 2013-08-14 | Janssen Pharmaceutica, N.V. | Indolin-2-one und aza-indolin-2-one |
| JP5536647B2 (ja) | 2007-07-27 | 2014-07-02 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ピロロピリミジン |
| HRP20170317T1 (hr) | 2008-02-15 | 2017-04-21 | Rigel Pharmaceuticals, Inc. | Spojevi pirimidin-2-amina i njihova uporaba kao inhibitora jak kinaza |
| US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
| AU2009244897B2 (en) | 2008-04-16 | 2014-11-13 | Alexion Pharmaceuticals, Inc. | 2, 6-diamino- pyrimidin- 5-yl-carboxamides as syk or JAK kinases inhibitors |
| WO2009131687A2 (en) | 2008-04-22 | 2009-10-29 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
| AU2009324894B2 (en) | 2008-11-25 | 2015-04-09 | University Of Rochester | MLK inhibitors and methods of use |
| WO2011149950A2 (en) | 2010-05-24 | 2011-12-01 | University Of Rochester | Bicyclic heteroaryl kinase inhibitors and methods of use |
| EP2635557A2 (de) | 2010-11-01 | 2013-09-11 | Portola Pharmaceuticals, Inc. | Nicotinamide als jak-kinasemodulatoren |
| US8877760B2 (en) | 2011-11-23 | 2014-11-04 | Portola Pharmaceuticals, Inc. | Substituted pyrazine-2-carboxamide kinase inhibitors |
| ES2748873T3 (es) * | 2012-01-26 | 2020-03-18 | Angion Biomedica Corp | Compuestos antifibróticos y usos de los mismos |
| EP2903970A4 (de) | 2012-10-08 | 2016-11-30 | Portola Pharm Inc | Substituierte pyrimidinylkinasehemmer |
| EP2925319B1 (de) | 2012-11-30 | 2019-01-09 | University Of Rochester | Mixed-lineage-kinaseinhibitoren für hiv/aids-therapien |
| PE20211054A1 (es) * | 2018-10-05 | 2021-06-07 | Ichnos Sciences S A | Compuestos de indolinona para uso como inhibidores de map4k1 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998050356A1 (en) * | 1997-05-07 | 1998-11-12 | Sugen, Inc. | 2-indolinone derivatives as modulators of protein kinase activity |
| DE19816624A1 (de) * | 1998-04-15 | 1999-10-21 | Boehringer Ingelheim Pharma | Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel |
-
1999
- 1999-03-04 GB GBGB9904995.9A patent/GB9904995D0/en not_active Ceased
-
2000
- 2000-03-03 EP EP00917713A patent/EP1180105B1/de not_active Expired - Lifetime
- 2000-03-03 WO PCT/US2000/005583 patent/WO2000055159A2/en not_active Ceased
- 2000-03-03 DE DE60002714T patent/DE60002714T2/de not_active Expired - Fee Related
- 2000-03-03 AU AU38645/00A patent/AU3864500A/en not_active Abandoned
- 2000-03-03 ES ES00917713T patent/ES2199156T3/es not_active Expired - Lifetime
- 2000-03-03 JP JP2000605588A patent/JP2003502280A/ja active Pending
- 2000-03-03 AT AT00917713T patent/ATE240328T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| GB9904995D0 (en) | 1999-04-28 |
| JP2003502280A (ja) | 2003-01-21 |
| ATE240328T1 (de) | 2003-05-15 |
| WO2000055159A2 (en) | 2000-09-21 |
| AU3864500A (en) | 2000-10-04 |
| WO2000055159A3 (en) | 2001-11-29 |
| EP1180105B1 (de) | 2003-05-14 |
| ES2199156T3 (es) | 2004-02-16 |
| DE60002714T2 (de) | 2004-03-18 |
| EP1180105A2 (de) | 2002-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE240328T1 (de) | Substituierte azaoxindolederivate | |
| ATE381557T1 (de) | Rho-kinase inhibitoren | |
| YU84603A (sh) | Novi inhibitori tirozin kinaze | |
| MY134783A (en) | Rho-kinase inhibitors | |
| MY142915A (en) | Rho-kinase inhibitors | |
| EA200900152A1 (ru) | Ингибиторы пирролотриазинкиназы | |
| ATE343575T1 (de) | Azaoxoindol derivate als trk protein kinase hemmstoffe zur behandlung von krebs und chronischem schmerz | |
| PL406680A1 (pl) | Inhibitory kinaz tyrozynowych | |
| TR200201505T2 (tr) | Terapötik maddeler olarak pirazolopirimidinler | |
| ATE371656T1 (de) | Heteroaryl-pyrimidinderivate als jak-inhibitoren | |
| WO2004087699A3 (en) | Thiazoles useful as inhibitors of protein kinases | |
| WO2004087698A3 (en) | Thiazoles useful as inhibitors of protein kinases | |
| EA200501009A1 (ru) | Замещённые пирролопиразольные производные в качестве ингибиторов киназы | |
| DK1678166T3 (da) | Proteinkinaseinhibitorer | |
| TW200613306A (en) | Imidazotriazines as protein kinase inhibitors | |
| MXPA04001037A (es) | Derivados de n-fenilpirrol guanidina como ligandos del receptor de melanocortina. | |
| MXPA03011484A (es) | Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades. | |
| BRPI0412347A (pt) | 2-aminofenil-4-fenilpiridinas como inibidores de quinase | |
| TW200630374A (en) | Thiazolyldihydroindazoles | |
| NO20061415L (no) | Kinazolinderivater | |
| ATE368643T1 (de) | Faktor xa benzamidin inhibitoren | |
| NO20044526L (no) | Hemisterlinderivater og anvendelser derav | |
| ATE238981T1 (de) | Antitumorwirkstoffe | |
| PT1165544E (pt) | 1,4-di-hidroindeno¬1,2-c|pirazoles substituidos como inibidores de tirosina-quinase | |
| DE60106409D1 (de) | 3-aminopyrazole als inhibitoren von cyclinabhängigen kinasen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |